核心观点 - Rosen Law Firm宣布对Cassava Sciences, Inc.提起集体诉讼,指控其在2024年2月7日至11月24日期间发布虚假信息,误导投资者 [1][5] 诉讼详情 - 诉讼指控Cassava在Class Period内制造了其拥有可靠信息关于药物前景和预期增长的虚假印象,同时淡化了药物失败的风险 [5] - Cassava对其主要药物候选者simufilam的信心声明和基于Phase 2研究统计上不显著数据的依赖,未能反映simufilam的实际潜力 [5] - Cassava没有一种药物能够减缓阿尔茨海默病的进展,即使是在治疗轻度和中度病例时 [5] - 当真实情况进入市场时,投资者遭受了损失 [5] 参与诉讼 - 在Class Period内购买Cassava证券的投资者可能有资格获得赔偿,无需支付任何费用 [2] - 要加入Cassava集体诉讼,可以访问https://rosenlegal.com/submit-form/?case_id=22374或联系Phillip Kim, Esq. [3][6] - 希望担任首席原告的投资者必须在2025年2月10日前向法院提出动议 [1][3] Rosen Law Firm介绍 - Rosen Law Firm专注于证券集体诉讼和股东衍生诉讼,代表全球投资者 [4] - 该律所曾在2017年ISS证券集体诉讼服务排名中位列第一,自2013年以来每年都位列前四 [4] - 2019年,该律所为投资者追回了超过4.38亿美元 [4] - 创始合伙人Laurence Rosen被law360评为2020年原告酒吧的泰坦 [4]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Cassava To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Cassava between February 7, 2024 and November 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Dec. 18, 2024 /PRNewswi ...

NEW YORK, Dec. 17, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/ps ...

SAN DIEGO, Dec. 16, 2024 /PRNewswire/ -- Robbins LLP announces that a class action was filed on behalf of all investors who purchased or otherwise acquired Cassava Sciences, Inc. (NASDAQ: SAVA) securities between February 7, 2024 and November 24, 2024. Cassava is a clinical stage biotechnology company, with a focus on developing drugs for neurodegenerative diseases.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Invest ...

NEW YORK, Dec. 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form-2/?id=116401&from=4CLASS PERIOD: Februar ...

NEW YORK, Dec. 13, 2024 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 10, 2025.So what: If you purchased Cassava securities during the C ...

Cassava Sciences’ (SAVA) stock shed more than 80% of market value on Monday after the company reported that its lead pipeline drug, simufilam, failed to meet the primary endpoints in a late study for Alzheimer’s disease (AD).SAVA releases top-line results from the ReThink-ALZ study, which evaluated simufilam in patients with mild-to-moderate AD. Treatment with the drug failed to achieve a significant reduction in cognitive or functional decline in AD patients when compared to placebo over a 52-week period, ...

文章核心观点 - Cassava Sciences, Inc. (SAVA) 近期股价下跌83.9%，但因处于超卖状态且分析师普遍上调盈利预期，股价可能即将反弹 [1][5][6][7] 超卖股票的识别方法 - 使用相对强弱指数 (RSI) 识别超卖股票，RSI低于30通常被视为超卖 [2] - RSI帮助投资者快速判断股价是否接近反转点，即使基本面良好，股价也会在超买和超卖之间波动 [3] SAVA的技术分析 - SAVA的RSI读数为21.7，表明卖压可能正在减弱，股价有望反弹 [5] - SAVA的Zacks排名为2 (买入)，表明其基于盈利预期修订和EPS惊喜的排名位于前20%，进一步支持股价反弹的潜力 [7] SAVA的基本面分析 - 分析师在过去30天内将SAVA的当前年度盈利预期上调了36.3%，通常这种上调趋势会转化为股价的短期上涨 [6]

文章核心观点 - Cassava Sciences的阿尔茨海默病治疗药物Simufilam在Phase 3试验中未能达到主要终点，导致股价大幅下跌 84.6% [2][3][16] 公司动态 - Cassava Sciences报告其Phase 3 ReThink-ALZ研究的顶线结果未达到主要终点，导致股价显著下跌 [2] - 公司计划在即将举行的会议上展示数据，Simufilam显示出良好的安全性 [2] - 公司CEO Rick Barry称结果对患者及其家属来说是令人失望的 [4] - 股价在周一早上迅速下跌超过80% [8] - 股价周一收盘下跌84.6%，达到$4.06，创下新的52周低点 [16] 市场反应 - 知名制药行业人物Martin Shkreli在周日晚上预测了股价的下跌 [2] - Shkreli在Twitter上建议在Robinhood或Interactive Brokers上做空SAVA股票 [6] - 股价在公司更新后迅速下跌超过80% [8] - Citron Research在Twitter上赞扬了Shkreli对Cassava Sciences的预测 [15] 行业背景 - Shkreli指出，阿尔茨海默病市场是一个非常难以瞄准的市场，过去98%的Phase 3试验都失败了 [9] - Shkreli预测Cassava的Phase 3试验可能会失败，因为它是针对症状性患者的 [9] - Shkreli称Cassava的股价可能会跌至其现金价值水平，即每股$2到$3 [11] - Shkreli曾因在制药行业的激进行为而闻名，包括将Daraprim的价格从$13.50提高到$750 [12] - Shkreli因证券欺诈被判刑，并被终身禁止进入制药行业 [12]

文章核心观点 - Cassava Sciences的实验性药物Simufilam在治疗阿尔茨海默病的三期临床试验中失败，导致公司股价在盘前交易中暴跌80%，公司决定终止另一项三期试验和开放标签试验 [1][2][7] 公司动态 - Cassava Sciences的Simufilam药物在三期临床试验中未能显示出“显著减少认知或功能衰退”的效果，该药物旨在治疗轻度至中度阿尔茨海默病患者 [2] - 公司CEO Rick Barry表示，试验结果令人失望，公司将终止另一项三期试验和开放标签试验 [3][4][5] - 公司曾在9月份与美国证券交易委员会(SEC)达成4000万美元的和解，原因是涉嫌操纵其阿尔茨海默病药物的临床试验数据 [6] 市场反应 - Cassava Sciences股价在盘前交易中暴跌80%，年初至今的涨幅降至约18% [7]